Baird analyst Colleen Kusy raised the firm’s price target on Apellis to $115 from $105 and keeps an Outperform rating on the shares. The firm said its survey data showed a storng increase in Syfovre prescriptions over its last survey leading to increase estimates and its price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APLS:
- Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
- Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS